• Lack Of Social Media Guidance From The FDA: Push Forward Or Put Programs On Pause?
    Here I was thinking that this article would be a piece of cake. The FDA intended to issue its guidance on how pharmaceutical companies could use social media by the end of 2010. I thought for sure this column would be prime real estate.
  • The Relevance Question: Balancing Brand Benefit With Patient Centricity
    At the 2010 ePatient conference in October, the Lance Armstrong Foundation reiterated Lance's belief that it is "the obligation of the cured" to help others navigate a health crisis. Pharma companies fundamentally exist to fulfill this obligation and advance patient health. While this mission is commendable, at the end of the day, big Pharma is big business too. And business is suffering as Pharma becomes increasingly peripheral to the healthcare conversation.

    The price of admission for having a business in five years is to remain relevant to your consumers. But how can an industry remain relevant when customers ...

  • 'Collaborative Care' Platforms Are The Future
    By bringing the doctor and patient into the mix and providing a platform where they can seriously discuss both disease and solution, a pharmaceutical company could be taking leaps into health care's future. The technologies are there. What we need is imagination and investment to create collaborative care platforms that will evolve doctor-patient dialogue to a whole new level.
  • Healthy Observations: The Journey To Diagnosing An Illness
    Whether it's an ache in your back, your heart starts beating like it's on overdrive or maybe you spend a good part of your day in the bathroom, dealing with your health is one of those things people would rather not do. So they put it off for as long as they possibly can, until one day things get bad and that usually motivates them to deal with their health and to begin their journey to finding out what's actually wrong with them.
  • Compliance Concerns? Maybe Focus On Curation
    While no single piece of information would convince an audience that a pharma company didn't have ulterior motives, the eventual cumulative effect of providing such a service could convince many that the company is truly interested in the wellness of its customers.